The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
IDO Inhibitors-Global Market Insights and Sales Trends 2024
Synopsis
The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
The global IDO Inhibitors market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of IDO Inhibitors in various end use industries. The expanding demands from the Metastatic Melanoma, Metastatic Pancreatic Cancer, mCRPC and Malignant Glioma, are propelling IDO Inhibitors market. Dual IDO1/TDO inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Covalent IDO inhibitors segment is estimated at % CAGR for the next seven-year period.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for IDO Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global IDO Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global IDO Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, IDO Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of IDO Inhibitors covered in this report include Pfizer, Bristol-Myers Squibb and Kyowa Hakko Kirin, etc.
The global IDO Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
Global IDO Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global IDO Inhibitors market, Segment by Type:
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors
Global IDO Inhibitors market, by Application
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of IDO Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of IDO Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
The global IDO Inhibitors market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of IDO Inhibitors in various end use industries. The expanding demands from the Metastatic Melanoma, Metastatic Pancreatic Cancer, mCRPC and Malignant Glioma, are propelling IDO Inhibitors market. Dual IDO1/TDO inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Covalent IDO inhibitors segment is estimated at % CAGR for the next seven-year period.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for IDO Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global IDO Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global IDO Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, IDO Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of IDO Inhibitors covered in this report include Pfizer, Bristol-Myers Squibb and Kyowa Hakko Kirin, etc.
The global IDO Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
Global IDO Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global IDO Inhibitors market, Segment by Type:
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors
Global IDO Inhibitors market, by Application
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of IDO Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of IDO Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 IDO Inhibitors Market Overview
1.1 IDO Inhibitors Product Overview
1.2 IDO Inhibitors Market Segment by Type
1.2.1 Dual IDO1/TDO inhibitors
1.2.2 Covalent IDO inhibitors
1.3 Global IDO Inhibitors Market Size by Type
1.3.1 Global IDO Inhibitors Market Size Overview by Type (2018-2029)
1.3.2 Global IDO Inhibitors Historic Market Size Review by Type (2018-2023)
1.3.3 Global IDO Inhibitors Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America IDO Inhibitors Sales Breakdown by Type (2018-2023)
1.4.2 Europe IDO Inhibitors Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific IDO Inhibitors Sales Breakdown by Type (2018-2023)
1.4.4 Latin America IDO Inhibitors Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa IDO Inhibitors Sales Breakdown by Type (2018-2023)
2 Global IDO Inhibitors Market Competition by Company
2.1 Global Top Players by IDO Inhibitors Sales (2018-2023)
2.2 Global Top Players by IDO Inhibitors Revenue (2018-2023)
2.3 Global Top Players by IDO Inhibitors Price (2018-2023)
2.4 Global Top Manufacturers IDO Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 IDO Inhibitors Market Competitive Situation and Trends
2.5.1 IDO Inhibitors Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by IDO Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in IDO Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into IDO Inhibitors Market
2.8 Key Manufacturers IDO Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 IDO Inhibitors Status and Outlook by Region
3.1 Global IDO Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global IDO Inhibitors Historic Market Size by Region
3.2.1 Global IDO Inhibitors Sales in Volume by Region (2018-2023)
3.2.2 Global IDO Inhibitors Sales in Value by Region (2018-2023)
3.2.3 Global IDO Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global IDO Inhibitors Forecasted Market Size by Region
3.3.1 Global IDO Inhibitors Sales in Volume by Region (2024-2029)
3.3.2 Global IDO Inhibitors Sales in Value by Region (2024-2029)
3.3.3 Global IDO Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global IDO Inhibitors by Application
4.1 IDO Inhibitors Market Segment by Application
4.1.1 Metastatic Melanoma
4.1.2 Metastatic Pancreatic Cancer
4.1.3 mCRPC
4.1.4 Malignant Glioma
4.1.5 Astrocytoma
4.1.6 Breast Cancer
4.2 Global IDO Inhibitors Market Size by Application
4.2.1 Global IDO Inhibitors Market Size Overview by Application (2018-2029)
4.2.2 Global IDO Inhibitors Historic Market Size Review by Application (2018-2023)
4.2.3 Global IDO Inhibitors Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America IDO Inhibitors Sales Breakdown by Application (2018-2023)
4.3.2 Europe IDO Inhibitors Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific IDO Inhibitors Sales Breakdown by Application (2018-2023)
4.3.4 Latin America IDO Inhibitors Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa IDO Inhibitors Sales Breakdown by Application (2018-2023)
5 North America IDO Inhibitors by Country
5.1 North America IDO Inhibitors Historic Market Size by Country
5.1.1 North America IDO Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America IDO Inhibitors Sales in Volume by Country (2018-2023)
5.1.3 North America IDO Inhibitors Sales in Value by Country (2018-2023)
5.2 North America IDO Inhibitors Forecasted Market Size by Country
5.2.1 North America IDO Inhibitors Sales in Volume by Country (2024-2029)
5.2.2 North America IDO Inhibitors Sales in Value by Country (2024-2029)
6 Europe IDO Inhibitors by Country
6.1 Europe IDO Inhibitors Historic Market Size by Country
6.1.1 Europe IDO Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe IDO Inhibitors Sales in Volume by Country (2018-2023)
6.1.3 Europe IDO Inhibitors Sales in Value by Country (2018-2023)
6.2 Europe IDO Inhibitors Forecasted Market Size by Country
6.2.1 Europe IDO Inhibitors Sales in Volume by Country (2024-2029)
6.2.2 Europe IDO Inhibitors Sales in Value by Country (2024-2029)
7 Asia-Pacific IDO Inhibitors by Region
7.1 Asia-Pacific IDO Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific IDO Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific IDO Inhibitors Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific IDO Inhibitors Sales in Value by Region (2018-2023)
7.2 Asia-Pacific IDO Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific IDO Inhibitors Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific IDO Inhibitors Sales in Value by Region (2024-2029)
8 Latin America IDO Inhibitors by Country
8.1 Latin America IDO Inhibitors Historic Market Size by Country
8.1.1 Latin America IDO Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America IDO Inhibitors Sales in Volume by Country (2018-2023)
8.1.3 Latin America IDO Inhibitors Sales in Value by Country (2018-2023)
8.2 Latin America IDO Inhibitors Forecasted Market Size by Country
8.2.1 Latin America IDO Inhibitors Sales in Volume by Country (2024-2029)
8.2.2 Latin America IDO Inhibitors Sales in Value by Country (2024-2029)
9 Middle East and Africa IDO Inhibitors by Country
9.1 Middle East and Africa IDO Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa IDO Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa IDO Inhibitors Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa IDO Inhibitors Sales in Value by Country (2018-2023)
9.2 Middle East and Africa IDO Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa IDO Inhibitors Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa IDO Inhibitors Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer IDO Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer IDO Inhibitors Products Offered
10.1.5 Pfizer Recent Development
10.2 Bristol-Myers Squibb
10.2.1 Bristol-Myers Squibb Company Information
10.2.2 Bristol-Myers Squibb Introduction and Business Overview
10.2.3 Bristol-Myers Squibb IDO Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Bristol-Myers Squibb IDO Inhibitors Products Offered
10.2.5 Bristol-Myers Squibb Recent Development
10.3 Kyowa Hakko Kirin
10.3.1 Kyowa Hakko Kirin Company Information
10.3.2 Kyowa Hakko Kirin Introduction and Business Overview
10.3.3 Kyowa Hakko Kirin IDO Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Kyowa Hakko Kirin IDO Inhibitors Products Offered
10.3.5 Kyowa Hakko Kirin Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 IDO Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 IDO Inhibitors Industrial Chain Analysis
11.4 IDO Inhibitors Market Dynamics
11.4.1 IDO Inhibitors Industry Trends
11.4.2 IDO Inhibitors Market Drivers
11.4.3 IDO Inhibitors Market Challenges
11.4.4 IDO Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 IDO Inhibitors Distributors
12.3 IDO Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
